Home › Compare › WEMXF vs ABBV
WEMXF yields 685.38% · ABBV yields 3.06%● Live data
📍 WEMXF pulled ahead of the other in Year 1
Combined, WEMXF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of WEMXF + ABBV for your $10,000?
Weimob Inc., an investment holding company, provides cloud-based commerce and marketing solutions in the People's Republic of China. It operates through Subscription Solutions, Merchant Solutions, and Digital Media segments. The Subscription Solutions segment provides cloud-hosted commerce and marketing SaaS products; customised software, such as ERP solutions; and other software related services, as well as WeiMall, Smart Retail, Smart Catering, Smart Hotel, Heading ERP, and others for e-commerce, retail, catering, hotel, local life, and other industries. The Merchant Solutions segment offers value-added services for merchants to meet merchants' online digital commerce and marketing needs, including assisting merchants to purchase online advertising traffic in various media platforms. The Digital Media segment provides advertisement placement services for merchants. The company was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.
Full WEMXF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.